

# Elucidation of Mechanism of Action and Next-Generation Seed Discovery for Commercialization of Bacterial Consortium AUN



Eijiro Miyako, Ph.D.  
Professor, Institute of Multidisciplinary Research for Advanced Materials (IMRAM),  
Tohoku University

# S1-226104

Professor, Institute of Multidisciplinary Research for Advanced Materials (IMRAM),  
Tohoku University

## Vision

- Establish a next-generation bacterial therapeutic platform for refractory solid tumors.
- Provide a novel mechanism of action for treatment-resistant cancers.
- Develop microbiome-based therapeutics targeting the tumor microenvironment.
- Become a global leader in non-GMO bacterial therapeutics.
- Expand into multiple cancer indications and international markets.
- Build an industrial platform for live biotherapeutic product development.

## Marketability

- Targets refractory solid tumors, including immune checkpoint inhibitor-resistant cancers.
- Significant unmet medical needs remain in solid tumor oncology.
- The global oncology market continues to expand, particularly for next-generation therapeutic modalities.
- The field of bacterial therapeutics is attracting increasing global attention as a next-generation drug discovery area.

## Innovation

- Unique therapeutic modality based on a non-genetically engineered natural bacterial consortium.
- Selective proliferation within hypoxic tumor microenvironments.
- Potent synergistic antitumor effects mediated by dual bacterial interactions.
- Potential safety advantage through self-limiting bacterial clearance.
- Regulatory advantages as a non-GMO bacterial therapeutic platform.
- Strong intellectual property position supported by granted core patents.

## Partnering

### 【 Expected partners 】

We are keen to explore collaboration with the following partners. Pharmaceuticals · CMO/CDMO/CRO/SMO · Venture capitals

### 【 Expectation 】

Startup support, non-clinical studies, Phase I clinical trial design and execution, and supply of combination drugs

## Research Outline

Key Words: #Microbiome #ImmuneResponse #Metabolism #LiveBiotherapeutics

- We are developing a novel cancer therapeutic modality based on a naturally derived dual-bacterial consortium (AUN).
- AUN selectively accumulates and proliferates within hypoxic tumor microenvironments, enabling localized antitumor activity while minimizing effects on normal tissues.
- Synergistic interaction between the two bacterial strains generate potent antitumor activity beyond that achieved by single-strain administration.
- Unlike conventional genetically engineered bacterial therapeutics, AUN utilizes natural bacterial strains and may reduce regulatory burdens associated with GMO products.
- Manufacturing process development, quality control, formulation, and CMC development for injectable live biotherapeutic products are ongoing.
- This technology aims to establish a novel therapeutic option for refractory solid tumors and immune therapy-resistant cancers.

